Small Molecules and therapeutics. Merck Exploratory Science Center (Merck ESC) is focused on improving immunotherapy outcomes through the microbiome.
COVID-19: (04/27/20) Working with Seattle's Institute for Systems Biology (ISB) on targets for vaccines and therapeutics.
Merck is working on two vaccines against COVID-19. The first vaccine is being developed with Themis Bioscience and is based on the company's measles virus vector. The second vaccine candidate will be developed in conjunction with IAVI and will use the same technology as Merck's Ebola Zaire vaccine.
Merck is also collaborating with Ridgeback Bio on an antiviral drug (EIDD-2801) to treat COVID-19 infections.